Evidence map›Paper›PMID 42192883›Full record

ReviewCancers2026

Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.

Luca Orecchia, Simone Steffani, Andrea Micillo, Roberto Miano, Eric Walser, Guglielmo Manenti

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luca OrecchiaDepartment of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
Simone SteffaniDiagnostic Imaging Department, AOU Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0009-0008-2280-6757
Andrea MicilloDiagnostic Imaging Unit, Casa di Cura Villa Delle Querce, 00040 Nemi, Italy.
Roberto MianoDepartment of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-2445-1204
Eric WalserSperling Prostate Center, Delray Beach, FL 33445, USA.ORCID 0000-0002-4784-6295
Guglielmo ManentiDiagnostic Imaging Department, AOU Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-7659-5392

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management of localized prostate cancer (PCa) suffers from the dilemma between the overtreatment associated with radical surgery and the uncertainty of active surveillance, highlighting a significant therapeutic gap specifically for intermediate-risk patients and selected low-risk patients. Focal therapy (FT) emerges as an advanced technological solution to balance rigorous oncological control with anatomical and functional preservation.

methodsA narrative review of the literature was conducted to analyze the physical principles underlying various ablative energies (thermal, cryogenic, and non-thermal) as well as radiation-based focal approaches. The review examines the oncological rationale of targeted ablation, recent innovations in imaging, and the expanding clinical scenarios for FT application.

resultsEvidence supports the oncological rationale of "Index Lesion" ablation as a targeted curative strategy for clinically significant disease, rather than merely a palliative one. The review highlights the emerging concept of "pushing the disease" and demonstrates the valuable role of salvage focal therapy in the setting of radio-recurrent carcinoma. Furthermore, recent innovations in multiparametric magnetic resonance imaging (mpMRI) and fusion systems have significantly refined patient selection, rendering this minimally invasive approach highly targeted.

conclusionsThe current barrier to the universal adoption of focal therapy is the lack of a standardized consensus on the definitions of therapeutic failure and the inadequacy of traditional PSA-based criteria. However, evidence suggests that FT represents a promising, organ-sparing alternative for carefully selected patients with localized PCa, though long-term comparative data are still required.

Indexed as

cryotherapyfocal therapyhigh-intensity focused ultrasoundhistotripsyindex lesionirreversible electroporationmultiparametric MRIprostate cancersalvage therapytransperineal laser ablation

Identifiers

PMID42192883
PMCPMC13204033

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.